{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:34:58Z","timestamp":1789472098810,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: This study aims to retrospectively analyze the clinical and imaging data of 101 patients with lung adenocarcinoma who underwent [18F]FDG PET\/CT examination and were pathologically confirmed in the Department of Nuclear Medicine at Peking University Cancer Hospital. This study explores the predictive value and important features of [18F]FDG PET\/CT radiomics for PD-L1 expression levels in lung adenocarcinoma patients, assisting in screening patients who may benefit from immunotherapy. Methods: 101 patients with histologically confirmed lung adenocarcinoma who received pre-treatment [18F] FDG PET\/CT were included. Among them, 44 patients were determined to be PD-L1 positive and 57 patients were determined to be PD-L1 negative based on immunohistochemical assays. Clinical data, PET\/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics were included in the modeling. Random Forest was used in feature denoising, while Forward Stepwise Regression and the Least Absolute Shrinkage and Selection Operator were used in feature selection. Models based on Tree, Discriminant, Logistic Regression, and Support Vector Machine were trained and evaluatedto explore the value of clinical data, PET\/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics. Results: All models showed some predictive ability in distinguishing PD-L1 positive from PD-L1 negative samples. Among the multimodal imaging, clinical data were incorporated into the models, with clinical stage and gender selected by Forward Stepwise Regression, while clinical stage, smoking history, and gender were selected by LASSO. When incorporating clinical data and thin-section CT-derived images into the models, nodular type, spiculation, and CT Shape Flatness were selected by Forward Stepwise Regression, while nodular type and spiculation were selected by LASSO. When incorporating clinical data, PET\/CT radiomics, observed CT characteristics, and conventional metabolic information. Forward Stepwise Regression selected TLGlean, MTV, nodule component, PET Shape Sphericity, while LASSO selected SULmax, MTV, nodular type, PET Shape Sphericity, and spiculation. Conclusions: The integration of clinical data, PET\/CT radiomics, and conventional metabolic parameters effectively predicted PD-L1 expression, thereby assisting the selection of patients who would benefit from immunotherapy. Observed CT characteristics and conventional metabolic information play an important role in predicting PD-L1 expression levels.<\/jats:p>","DOI":"10.3390\/diagnostics15050543","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:52:47Z","timestamp":1740394367000},"page":"543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET\/CT Radiomic Features"],"prefix":"10.3390","volume":"15","author":[{"given":"Huiyuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Beijing Chest Hospital, Capital Medical University\/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6590-011X","authenticated-orcid":false,"given":"Xiangxi","family":"Meng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"United Imaging Healthcare Group, Central Research Institute, Shanghai 201900, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5626-5101","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"1023","article-title":"Quality of life of patients with lung cancer","volume":"9","author":"Polanski","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"He, J., Hu, Y., Hu, M., and Li, B. (2015). Development of PD-1\/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci. Rep., 5.","DOI":"10.1038\/srep13110"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/1078-0432.CCR-14-2959","article-title":"Immune checkpoint modulation for non-small cell lung cancer","volume":"21","author":"Soria","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00259-007-0449-7","article-title":"Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer","volume":"34","author":"Yamamoto","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(04)01564-5","article-title":"Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review","volume":"5","author":"Vansteenkiste","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ijrobp.2008.08.022","article-title":"The Use of Positron Emission Tomography (PET) in the Staging\/Evaluation, Treatment, and Follow-Up of Patients with Lung Cancer: A Critical Review","volume":"72","author":"Hicks","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/cam4.1215","article-title":"Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"6","author":"Takada","year":"2017","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13550-020-00639-9","article-title":"PD-L1 expression correlation with metabolic parameters of FDG PET\/CT and clinicopathological characteristics in non-small cell lung cancer","volume":"10","author":"Wu","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_20","first-page":"449","article-title":"Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features","volume":"28","author":"Sun","year":"2020","journal-title":"J. Xray Sci. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/1759-7714.13352","article-title":"Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas","volume":"11","author":"Yoon","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: Extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.acra.2019.04.016","article-title":"Assessing PD-L1 Expression Level by Radiomic Features From PET\/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result","volume":"27","author":"Jiang","year":"2020","journal-title":"Acad. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.2147\/CMAR.S256871","article-title":"PD-L1 in Lung Adenocarcinoma: Insights into the Role of (18)F-FDG PET\/CT","volume":"12","author":"Cui","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00259-016-3425-2","article-title":"Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery","volume":"43","author":"Lopci","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/5\/543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:13Z","timestamp":1760028073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/5\/543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["diagnostics15050543"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15050543","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}